Showing 2401-2410 of 5268 results for "".
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- AbbVie: Rinvoq Hits AD Treat-to-Target Aims as Early as Week 2https://practicaldermatology.com/news/abbvie-rinvoq-hits-ad-treat-to-target-aims-as-early-as-week-2/2461142/Treatment with Rinvoq® (upadacitinib) 15mg or 30mg allows patients to rapidly achieve their initial three-month acceptable treatment target goal at Week 2, with consistent achievement through Week 16, results of a new analysis show. Using the framework of the recently developed evidence-based
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Phase 3 Data: Sun Pharma’s Winlevi Is Safe and Effective Acne Txhttps://practicaldermatology.com/news/phase-3-data-sun-pharmas-winlevi-is-safe-and-effective-acne-tx/2461134/Results from two Phase 3 pivotal clinical trials showed favorable safety and efficacy data for Winlevi (clascoterone) cream 1% in patients with acne aged 12 years and older. The findings were presented at the American Academy of Dermatol
- Poster: Interim Data Show Safety, Efficacy of Adbry for More than Three Yearshttps://practicaldermatology.com/news/poster-interim-data-show-safety-efficacy-of-adbry-for-more-than-three-years/2461129/Interim data support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate-to-severe atopic dermatitis (AD). Results were shared as a
- DERMWIRE Exclusive: FDA Clears Cutera’s AviClear Acne Devicehttps://practicaldermatology.com/news/dermwire-exclusive-fda-clears-cuteras-aviclear-acne-device/2461124/The U.S. Food and Drug Administration has cleared granted 510(k) clearance to Cutera’s AviClear acne device. This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne. AviClear targets acne at the source by selec
- Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301https://practicaldermatology.com/news/jeune-aesthetics-announces-positive-clinical-phase-1-efficacy-results-for-kb301/2461119/Aesthetics, Inc.’s KB301 demonstrated promise in proof-of-concept in the Phase 1 PEARL-1 study. Specifically, Cohort 2 of this trial evaluated KB301 for the improvement of fine lines and skin texture in the lower and upper cheek, and for improvement in skin thickness in
- Evommune Initiates Phase 1 Study of EVO101 for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/evommune-initiates-phase-1-study-of-evo101-for-inflammatory-skin-diseases/2461117/Evommune, Inc. has enrolled the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being
- Mount Sinai Health System Launches Alopecia Areata Center of Excellencehttps://practicaldermatology.com/news/mount-sinai-health-system-launches-alopecia-areata-center-of-excellence/2461115/In an effort to deliver outstanding comprehensive care and to employ revolutionary approaches to novel therapeutics around the skin condition alopecia areata, the Mount Sinai Health System has launched the Alopecia Areata Center of Excellence. Under the leadership of Director Emma Guttman-Yassky,
- It's Grant Season: NEA Announces 2022 Eczema Research Grant Cyclehttps://practicaldermatology.com/news/its-grant-season-nea-announces-2022-eczema-research-grant-cycle-1/2461109/The National Eczema Association's (NEA) 2022 research grant cycle is now open, with awards totaling $760,000. Applications must be received by June 1, 2022, at 5 p.m. PDT, and recipients will be announced in October 2022. As the largest private nonprofi